Lifeloc Reports Third Quarter 2026 Results

Lifeloc Technologies, Inc (LCTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeloc Reports Third Quarter 2026 Results WHEAT RIDGE, Colo., November 16, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quar

Event · Earnings
Original reporting
Published Nov 16, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LCTC
Bullish
medium confidence
Mentioned
$LCTC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LCTCBullishMed
01

Why it matters

The 8-K furnishes Q3 2026 financial results and a revised commercialization timeline for SpinDetect, shifting the expected path to future revenue and cash-flow funding needs.

02

Market read

Traders can update expectations for near-term profitability (gross margin and revenue growth) and reprice longer-dated growth optionality due to the SpinDetect launch delay.

03

What to watch

The company states it will defer core breath-alcohol upgrades and rely on current staff for beta testing, which could affect execution quality and the pace of subsequent multi-drug panel expansion.

Relevance 7/10Novelty 6/10Timing: after-hours filing on 2026-11-16

Background

Lifeloc Technologies is an OTC-listed manufacturer of evidential breath alcohol testers and is developing the SpinDetect centrifugal drug analyzer platform for rapid on-site quantitative drug detection.

Company-level read

Ticker impact

$LCTCBullishMedium confidence
Context

Lifeloc reports Q3 2026 revenue of $2.522M and updates SpinDetect commercialization timing to a limited launch in Q4 2027.

Expected impact

Shares may see modest support from revenue growth and margin improvement, but upside could be capped by the Q1 2027 to Q4 2027 delay for SpinDetect.

Evidence & confidence

The filing provides fresh quarterly financial datapoints and a specific change to the SpinDetect launch schedule, both directly affecting near-term expectations and longer-dated growth optionality.

Market effects

Highlights ongoing R&D intensity in breath alcohol and drug testing instrumentation, with commercialization risk tied to regulatory and validation timelines.

No clear regional spillover beyond a small OTC issuer’s reporting.

Limited global read-through; the drug analyzer platform is positioned for multiple use cases but remains pre-commercial.

Counterpoint

The improved gross margin may be driven by mix and price increases, while the core growth engine (SpinDetect) is pushed further out, increasing dilution or capital-access risk.

Key entities

  • Lifeloc Technologies, Inc.

    OTC-listed developer and manufacturer of breath alcohol and drug testing devices, reporting Q3 2026 results and SpinDetect timeline changes.

  • SpinDetect Centrifugal Drug Analyzer

    Oral-fluid centrifugal drug analyzer platform with beta testing planned for delta-9-THC and a revised limited commercial launch expected in Q4 2027.

  • L-series breath alcohol devices

    Newer breath alcohol lineup with smartphone pairing and temperature range features, positioned as incremental to FC-series devices.

Related articles

$LCTCMed

Lifeloc Reports Second Quarter 2026 Results

Lifeloc Technologies, Inc (LCTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeloc Reports Second Quarter 2026 Results WHEAT RIDGE, Colo., August 13, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quart

$NVDAHighAI 9/10

What's Going On With Nvidia Stock Wednesday

Nvidia (NVDA) reported quarterly earnings of $2.68 per share on revenue of $115.84 billion, beating estimates. Data center sales reached $107.6 billion. The company raised its revenue forecast for the current quarter and long-term growth outlook, but expects no revenue from China. Nvidia also expanded its stock buyback program.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.

$GLADMed

Gladstone Capital (GLAD) Q4 2026 Earnings Call Transcript

Gladstone Capital (GLAD) reported Q4 2026 earnings with net interest margin at 8.2%. Fee income was below average, but incentive fee credit covered 100% of regular distributions. Net asset value declined to $20.77 per share due to unrealized depreciation and a supplemental distribution. Total investment income rose 11.7% for the year, covering distributions at 104.5%. The company discussed its investment strategy and credit management, highlighting its focus on the lower middle market.